Related Experiment Videos
[The use of metamizole as a risk factor in the occurrence of agranulocytosis]
Abstract:
The risk of agranulocytosis following the use of metamizole was studied by the method of controlled cases. All cases of agranulocytosis and their control cases in Sofia for the period 1982-1986 were included in the study. The mean agranulocytosis morbidity for this period was 3.16 cases for one million population for one year. The etiologic fraction was 7.1%. The relative risk of agranulocytosis following the use of metamizole is 1.25, the maximal risk is 0.03 cases for one million persons using metamizole for one year and the maximal lethal risk is 0.007 cases for one million persons using metamizole for one year. The use of metamizole in Bulgaria for the same period was studied, too. The data presented as a number of defined daily doses used by 1000 population for one day show that the use of metamizole in this country is high. A tendency toward an increase of 7.3% per year was found during the investigation. At the same time the agranulocytosis morbidity remained constant during the period of investigation. The results of the study lead to the conclusion that the use of metamizole is not related to a higher risk of agranulocytosis.
Insights
This study found no increased risk of agranulocytosis from metamizole use. Agranulocytosis morbidity remained constant despite high metamizole consumption, indicating a lack of association.
Area of Science:
- Pharmacovigilance
- Epidemiology
- Drug Safety
Background:
- Metamizole is a widely used analgesic and antipyretic.
- Agranulocytosis is a rare but serious adverse effect associated with metamizole.
- Understanding the true risk is crucial for public health.
Purpose of the Study:
- To investigate the association between metamizole use and the risk of agranulocytosis.
- To determine the incidence and risk factors of agranulocytosis in Sofia, Bulgaria.
Main Methods:
- A controlled case study design was employed.
- Inclusion of all agranulocytosis cases and matched controls in Sofia (1982-1986).
- Analysis of metamizole consumption patterns in Bulgaria during the study period.
Main Results:
- The mean agranulocytosis morbidity was 3.16 cases per million population annually.
- The relative risk of agranulocytosis associated with metamizole was calculated as 1.25.
- Metamizole consumption in Bulgaria was high and increasing, yet agranulocytosis rates remained stable.
Conclusions:
- The study concludes that metamizole use is not associated with an elevated risk of agranulocytosis.
- Despite high drug usage, agranulocytosis incidence remained constant, suggesting a weak or non-existent link.